阿法替尼联合西妥昔单抗对比阿法替尼单药一线治疗EGFR突变NSCLC的随机试验:SWOG S1403最终结果
SWOG S1403是一项II期多中心随机试验,纳入174例初治EGFR突变晚期NSCLC患者,比较阿法替尼联合西妥昔单抗与阿法替尼单药的疗效。
要点
- 阿法替尼联合西妥昔单抗未改善初治EGFR突变NSCLC的PFS。
- 联合组3级及以上治疗相关不良事件发生率为72%,单药组为40%。
- 联合组30%患者因毒性停用西妥昔单抗,剂量调整更常见。
核心结论
- 在初治EGFR突变NSCLC中,阿法替尼联合西妥昔单抗相比阿法替尼单药未改善PFS、缓解率或OS。
研究设计与样本
- II期多中心随机试验,2015年3月25日至2018年4月23日随机分配174例患者,其中168例符合条件(联合组83例,单药组85例)。
- 患者为无既往晚期疾病治疗的EGFR突变NSCLC,随机接受阿法替尼40 mg口服每日联合西妥昔单抗500 mg/m2静脉每2周,或阿法替尼单药。
- 主要终点为PFS。
主要发现
- 联合组3级及以上治疗相关不良事件发生率为72%,单药组为40%,最常见为皮疹和腹泻。
- 联合组剂量调整更常见,30%患者因毒性停用西妥昔单抗。
关键数值与推荐
- 3级及以上治疗相关不良事件:联合组72% vs 单药组40%。
临床怎么用
- 不推荐在初治EGFR突变NSCLC中常规联合阿法替尼与西妥昔单抗,因无PFS获益且毒性增加。
- 联合方案在获得性耐药背景下虽有活性,但一线应用需谨慎权衡毒性。
局限性
- 中期分析时证据不足支持继续入组,试验提前关闭。
- 为II期试验,样本量有限(168例符合条件)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR TKIs. We studied whether the combination of afatinib plus cetuximab compared with afatinib alone would improve progression-free survival (PFS) in patients with treatment-naive EGFR-mutant non-small-cell lung cancer (NSCLC) by preventing or delaying resistance. METHODS: Patients with EGFR-mutant NSCLC without prior treatment of advanced disease were enrolled in this phase II, multicenter trial and randomly assigned to receive afatinib 40 mg orally daily plus cetuximab 500 mg/m2 intravenously every 2 weeks or afatinib alone. The primary end point was PFS. RESULTS: Between March 25, 2015 and April 23, 2018, 174 patients were randomly assigned, and 168 (83 on afatinib + cetuximab and 85 on afatinib) were eligible. There was no improvement in PFS in patients receiving afatinib plus cetuximab compared with afatinib alone (hazard ratio [HR], 1.01; 95% CI, 0.72 to 1.43; P = .94; median, 11.9 months v 13.4 months). Similarly, there was no difference in response rate (67% v 74%; P = .38) or overall survival (HR, 0.82; 95% CI, 0.50 to 1.36; P = .44). Toxicity was greater with the combination: grade ≥ 3 adverse events related to treatment occurred in 72% of patients receiving afatinib plus cetuximab compared with 40% of those receiving afatinib alone, most commonly rash and diarrhea. Dose reductions were more common in patients receiving the combination, and 30% of patients in this arm discontinued cetuximab due to toxicity. At interim analysis, there was insufficient evidence to support continued accrual, and the trial was closed. CONCLUSIONS: The addition of cetuximab to afatinib did not improve outcomes in previously untreated EGFR-mutant NSCLC, despite recognized activity in the acquired resistance setting.
引用
- Goldberg SB, Redman MW, Lilenbaum R, et al. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. J Clin Oncol. 2020. PMID: 33021871. doi:10.1200/JCO.20.01149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。